Sarcopenia in Inflammatory Bowel Diseases: Reviewing Past Work to Pave the Path for the Future.
Sarcopenia in Inflammatory Bowel Diseases: Reviewing Past Work to Pave the Path for the Future.
复制标题
炎症性肠道疾病中的肌肉减少症：审查过去的工作以铺平未来的道路。
DOI：
10.1007/s11938-022-00389-8
复制
发表时间：
2022-09
期刊：
影响因子：
--
通讯作者：
Kochar, Bharati
中科院分区：
文献类型：
--
作者：
Faye, Adam S;Khan, Tasnin;Cautha, Sandhya;Kochar, Bharati
肌肉减少症是肌肉数量和力量的损失。它在炎症性肠病（IBD）患者中非常普遍，并与持续炎症期相关。这篇综述将总结该领域的先前工作，并强调未来的研究领域。在不同人群中，肌肉减少症的存在与不良结局相关。最近，肌肉减少症与IBD的不良术后结局和手术可能性增加有关。尽管如此，这些研究之间的显著异质性限制了得出明确结论的能力。肌肉减少症在炎症性肠病（IBD）中的重要性才刚刚开始被认识到。未来的研究评估它的效用作为一个危险分层工具和IBD的可修改的因素是必要的。
Sarcopenia is the loss of muscle quantity and strength. It is highly prevalent in patients with inflammatory bowel disease (IBD) and is associated with periods of ongoing inflammation. This review will summarize the prior work in the field and highlight areas for future research. The presence of sarcopenia has been associated with adverse outcomes in different populations. Most recently, sarcopenia has been associated with adverse postoperative outcomes and an increased likelihood of surgery in IBD. Despite this, significant heterogeneity among these studies limits the ability to draw definitive conclusions. The importance of sarcopenia in inflammatory bowel disease (IBD) is only beginning to be recognized. Future studies assessing it utility both as a risk stratification tool and a modifiable factor in IBD are needed.